[Immune potency of recombinant adeno-associated virus combined with recombinant adenovirus vaccine containing HIV-1 gp120].
OBJECTIVE
To study the immune effect of recombinant adeno-associated virus (rAAV) combined with recombinant adenovirus (rAdV) vaccine in BALB/c mice.


METHODS
The codon-modified HIV-1 gp120 gene was inserted into plasmid of adeno-associated virus and adenovirus vector separately. Then the rAAV and rAdV vaccines were constructed. BALB/c mice were immunized with rAAV and rAdV vaccines in different administration scheme. The IgG antibody was detected by ELISA and CTL response was detected by intracellular cytokine stain assay.


RESULTS
Both rAAV and rAdV vaccine could express gp120 gene; the mice primed with rAAV at week 0, 2 and boosted with rAdV at week 5, 14 and 20 elicited the strongest gp120 specific CTL and IgG antibody response.


CONCLUSIONS
The mice primed with rAAV and boosted with rAdV could elicit specific CTL response and IgG antibody.
Feng
Xia
X
Department of Oncogenic Virus and HIV, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China.
Yu
Shuang-qing
SQ
Chen
Guo-min
GM
Wu
Xiao-bing
XB
Zuo
Jian-min
JM
Dong
Wen-ping
WP
Zhou
Ling
L
Zeng
Yi
Y
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D000229:Dependovirus / Q000235:genetics*; D005260:Female; D005822:Genetic Vectors; D015699:HIV Envelope Protein gp120 / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D015497:HIV-1; D007074:Immunoglobulin G / Q000097:blood; D007371:Interferon-gamma / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids; D011995:Recombination, Genetic; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology* / Q000378:metabolism
D015699:HIV Envelope Protein gp120; D007074:Immunoglobulin G; D019444:Vaccines, DNA; D007371:Interferon-gamma